NASDAQ: MLTXMoonlake Immunotherapeutics Stock
$46.60-0.16 (-0.34%)
Updated Sep 10, 2024
MLTX Price
$46.60
Fair Value Price
$9.11
Market Cap
$2.98B
52 Week Low
$35.11
52 Week High
$64.98
P/E
-52.36x
P/B
5.72x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$58.24M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.03
Operating Cash Flow
-$64M
Beta
0.49
Next Earnings
Nov 12, 2024
Ex-Dividend
N/A
Next Dividend
N/A
MLTX Overview
MoonLake Immunotherapeutics develops medicines for immunologic diseases, including inflammatory skin and joint diseases. It focuses on enhancing its novel tri-specific Nanobody Sonelokimab (SLK) product, an inhibitor to treat multiple inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F. The company is conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, and radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MLTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MLTX ($46.60) is overvalued by 411.57% relative to our estimate of its Fair Value price of $9.11 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MLTX ($46.60) is not significantly undervalued (411.57%) relative to our estimate of its Fair Value price of $9.11 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MLTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MLTX due diligence checks available for Premium users.
Be the first to know about important MLTX news, forecast changes, insider trades & much more!
MLTX News
Valuation
MLTX fair value
Fair Value of MLTX stock based on Discounted Cash Flow (DCF)
Price
$46.60
Fair Value
$9.11
Overvalued by
411.57%
MLTX ($46.60) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MLTX ($46.60) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MLTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MLTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-52.36x
Industry
-138.13x
Market
23.55x
MLTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.72x
Industry
6.29x
MLTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MLTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$24.8M
Profit Margin
0%
MLTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$544.9M
Liabilities
$14.8M
Debt to equity
0.03
MLTX's short-term assets ($536.88M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MLTX's short-term assets ($536.88M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MLTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$27.9M
Investing
-$87.7M
Financing
$0.0
MLTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MLTX vs Biotech Stocks
Moonlake Immunotherapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.